• Je něco špatně v tomto záznamu ?

Management of multiple sclerosis patients in central European countries: current needs and potential solutions

T. Berger, M. Adamczyk-Sowa, T. Csépány, F. Fazekas, T. Hojs Fabjan, D. Horáková, Z. Illes, E. Klimová, F. Leutmezer, K. Rejdak, C. Rozsa, S. Šega Jazbec, J. Szilasiová, P. Turčáni, M. Vachová, L. Vécsei, E. Havrdová,

. 2018 ; 11 (-) : 1756286418759189. [pub] 20180222

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc18009958

Multiple sclerosis (MS) experts in Europe are facing rapidly rising demands of excellence due to the increasing complexity of MS therapy and management. A central European expert board of MS experts met to identify needs and obstacles with respect to raising quality of MS care in central and Eastern European countries. There are substantial variations across countries regarding delivery of care and its cost structure, as well as access to treatment. To date, Eastern European countries are often less able to afford reimbursement of immunomodulatory agents than Western countries. Overall, approximately 40% of working-age patients are not working due to MS. Costs rise steeply with increasing disability; indirect costs constitute the bulk of the financial burden in patients with severe MS. Magnetic resonance imaging (MRI) assessment is meanwhile obligatory as the diagnostic interface in the management of MS patients. Recommended measures directed at improving quality of care include the collection of patient data in registries, enhanced education of healthcare professionals, implementation of national strategies aiming at reducing regional variation, optimization of approval processes, and removal of administrative barriers. Local partnerships with authorities such as those that represent the interests of employees can contribute to leverage the importance of epidemiological data. The need for education extends to (neuro)radiologists who are responsible for reporting MRI findings in expert quality. Dissemination of the Magnetic Resonance Imaging in MS (MAGNIMS) protocol would be an important step in this context. Also, clinical freedom of choice is rated as essential. Physicians should have access to a range of treatment options due to the complexity of disease. Guidelines such as the upcoming EAN-ECTRIMS clinical practice guideline also aim at providing a basis for argumentation in negotiations with national health authorities.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18009958
003      
CZ-PrNML
005      
20180405095801.0
007      
ta
008      
180404s2018 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1756286418759189 $2 doi
035    __
$a (PubMed)29511382
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Berger, Thomas $u Clinical Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria.
245    10
$a Management of multiple sclerosis patients in central European countries: current needs and potential solutions / $c T. Berger, M. Adamczyk-Sowa, T. Csépány, F. Fazekas, T. Hojs Fabjan, D. Horáková, Z. Illes, E. Klimová, F. Leutmezer, K. Rejdak, C. Rozsa, S. Šega Jazbec, J. Szilasiová, P. Turčáni, M. Vachová, L. Vécsei, E. Havrdová,
520    9_
$a Multiple sclerosis (MS) experts in Europe are facing rapidly rising demands of excellence due to the increasing complexity of MS therapy and management. A central European expert board of MS experts met to identify needs and obstacles with respect to raising quality of MS care in central and Eastern European countries. There are substantial variations across countries regarding delivery of care and its cost structure, as well as access to treatment. To date, Eastern European countries are often less able to afford reimbursement of immunomodulatory agents than Western countries. Overall, approximately 40% of working-age patients are not working due to MS. Costs rise steeply with increasing disability; indirect costs constitute the bulk of the financial burden in patients with severe MS. Magnetic resonance imaging (MRI) assessment is meanwhile obligatory as the diagnostic interface in the management of MS patients. Recommended measures directed at improving quality of care include the collection of patient data in registries, enhanced education of healthcare professionals, implementation of national strategies aiming at reducing regional variation, optimization of approval processes, and removal of administrative barriers. Local partnerships with authorities such as those that represent the interests of employees can contribute to leverage the importance of epidemiological data. The need for education extends to (neuro)radiologists who are responsible for reporting MRI findings in expert quality. Dissemination of the Magnetic Resonance Imaging in MS (MAGNIMS) protocol would be an important step in this context. Also, clinical freedom of choice is rated as essential. Physicians should have access to a range of treatment options due to the complexity of disease. Guidelines such as the upcoming EAN-ECTRIMS clinical practice guideline also aim at providing a basis for argumentation in negotiations with national health authorities.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Adamczyk-Sowa, Monika $u Department of Neurology in Zabrze, Medical University of Silesia, Katowice, Poland.
700    1_
$a Csépány, Tünde $u Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
700    1_
$a Fazekas, Franz $u Department of Neurology, Medical University of Graz, Graz, Austria.
700    1_
$a Hojs Fabjan, Tanja $u Department of Neurology, University Medical Centre Maribor, Maribor, Slovenia.
700    1_
$a Horáková, Dana $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Illes, Zsolt $u Department of Neurology, University of Southern Denmark, Odense, Denmark.
700    1_
$a Klimová, Eleonóra $u Department of Neurology, University of Prešov and Teaching Hospital of JA Reiman, Prešov, Slovakia.
700    1_
$a Leutmezer, Fritz $u Department of Neurology, Medical University of Vienna, Vienna, Austria.
700    1_
$a Rejdak, Konrad $u Department of Neurology, Medical University of Lublin, Lublin, Poland.
700    1_
$a Rozsa, Csilla $u Department of Neurology, Jahn Ferenc Dél-pesti Hospital, Budapest, Hungary.
700    1_
$a Šega Jazbec, Saša $u Department of Neurology, University of Ljubljana, Ljubljana, Slovenia.
700    1_
$a Szilasiová, Jarmila $u Department of Neurology, Pavol Jozef Šafárik University and University Hospital L Pasteur, Košice, Slovakia.
700    1_
$a Turčáni, Peter $u Department of Neurology, Comenius University, Bratislava, Slovakia.
700    1_
$a Vachová, Marta $u MS Centrum Teplice, Teplice, Czech Republic.
700    1_
$a Vécsei, László $u Department of Neurology and MTA-SZTE Neuroscience Research Group, University of Szeged, Szeged, Hungary.
700    1_
$a Havrdová, Eva $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
773    0_
$w MED00177176 $t Therapeutic advances in neurological disorders $x 1756-2856 $g Roč. 11, č. - (2018), s. 1756286418759189
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29511382 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180405095842 $b ABA008
999    __
$a ind $b bmc $g 1287443 $s 1006770
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 11 $c - $d 1756286418759189 $e 20180222 $i 1756-2856 $m Therapeutic advances in neurological disorders $n Ther Adv Neurol Disord $x MED00177176
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace